Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Optinose Inc (NQ: OPTN )

1.235 -0.015 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Optinose Inc

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
Conference Call and Webcast to be held November 9, 2023, at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the 2023 Cantor Global Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the Jefferies Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Optinose, Inc.
Via GlobeNewswire
Optinose to Present at the Needham Virtual Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces CEO Transition and Business Update
Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors 
From Optinose, Inc.
Via GlobeNewswire
Optinose Appoints Paul Spence as Chief Commercial Officer
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Departure of Acting Chief Financial Officer
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Proposed Public Offering of Common Stock and Warrants
From Optinose, Inc.
Via GlobeNewswire
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time 
From Optinose, Inc.
Via GlobeNewswire
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
From Optinose, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.